Table 2.
Univariate associations between the type of R/POD and key baseline and treatment characteristics.
| Baseline and Treatment Characteristics | Asymptomatic N = 153 |
Symptomatic N = 26 |
P-value* |
|---|---|---|---|
| Age at Diagnosis, Mean (SD) | 58 (9) | 53 (7) | 0.01 |
| Male Sex, N (%) | 90 (59) | 17 (65) | 0.53 |
| High Risk Cytogenetics**, N (%) | 24 (24) | 8 (53) | 0.03 |
| M-Protein, N (%) | |||
| FLC-only | 35 (23) | 3 (12) | 0.48 |
| IgA | 30 (20) | 5 (19) | |
| IgG | 87 (57) | 18 (69) | |
| IgM | 1 (1) | 0 (0) | |
| Abnormal Kappa/Lambda**, N (%) | 112 (90) | 16 (89) | 0.69 |
| Advanced ISS Stage (II+III)**, N (%) | 72 (56) | 10 (50) | 0.64 |
| LDH, Mean (SD) | 168 (61) | 199 (106) | 0.21 |
| Single Auto Infusion, N (%) | 129 (84) | 22 (85) | 0.99 |
| Months from Diagnosis to Transplant, Mean (SD) | 10.5 (7.9) | 11.9 (13.8) | 0.60 |
| Months from Treatment to Transplant, Mean (SD) | 7.5 (3.4) | 7.7 (3.4) | 0.74 |
| CR Best Response, N (%) | 77 (50) | 11 (42) | 0.45 |
| Any Maintenance Therapy N (%) | 27 (18) | 5 (19) | 0.79 |
| Time from Infusion to Serologic R/POD, Mean (SD) | 25.6 (18.2) | 14.2 (11.1) | |
| Median (IQR) | 20.9 (13.3-33.4) | 10.4 (4.8-21.2) | < 0.001 |
| Months from R/POD to prior Serologic Evaluation, Mean (SD) |
3.7 (4.6) | 3.6 (3.7) | 0.95 |
*
for differences in means/proportions across the two R/POD groups
**
denominator includes only those with an observed value